Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.64 |
| ▸ | MAOA | P21397 | 4/20 | 0.64 |
| ▸ | F10 | P00742 | 10/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | CALML3 | P27482 | 1/20 | 0.51 |
| ▸ | SDHA | P31040 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4093270 | 0.90 | MAOB (0.63) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL4082340 | 0.88 | MAOB (0.49) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL4099425 | 0.85 | MAOB (0.67) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL4082568 | 0.84 | MAOB (0.64) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL4099417 | 0.82 | MAOB (0.73) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL4082562 | 0.81 | MAOB (0.69) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL5216684 | 0.79 | MAOB (0.84) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL6040542 | 0.78 | MAOB (0.85) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL18410592 | 0.78 | MAOB (0.80) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL7846260 | 0.78 | MAOB (0.79) | MAOBMAOAF10LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005369-A1 | Oxazolidinone Compounds and Compositions and Methods Related Thereto | FERRER INTERNACIONAL S.A. (ES) | 2009-01-01 | — | — | US | disclosed |
| EP-1786805-A1 | OXAZOLIDINONE COMPOUNDS AND COMPOSITIONS AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006010756-A1 | OXAZOLIDINONE COMPOUNDS AND COMPOSITIONS AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S. A. (ES) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005369-A1 | Oxazolidinone Compounds and Compositions and Methods Related Thereto | OXA1L, MAOA, NR0B1 | MAOB 8/4885MAOA 2/4885F10 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.